A director at Amazon Com Inc sold 2,500 shares at 217.000USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
In July, the HSI and MSCI China index extended their growths, rising 2.9% mom and 4.5% mom respectively to reach their peak on 24 July before pulling pack in the latest week, as investors tend to take profit after the Politburo announcement. With another 90-day tariff delay from the US, we maintain a positive outlook for leading domestic stocks in healthcare and IT. New additions to our BUY list are JBM Healthcare and Lenovo. We take profit on CATL, Han’s Laser, KE Holdings and Longfor.
AMZN remains our Top Pick, based on 2H25/1H26 AWS revenue acceleration, albeit lagging GCP and Azure. That AWS appears to be more capacity constrained than Azure and GCP is not a big surprise. MSFT has the largest base of GPUs, while GOOGL has a larger custom silicon base. We expect AWS to accelerate as it closes the gap on custom silicon, ramping into Trainium3 later this year.
Figure 1. 2Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusGuidance notes: 2Q total revenue guidance of $159B to $164B; 2Q operating income guidance of $13.0B to $17.5B.In 2Q, total revenues grew +13.3% Y/Y, ~3% ahead of expectations, driven by outperformance across all segm
In this first take following tonight’s results, we focus on: 1. AWS revenue growth beats consensus but the real question is 2H acceleration 2. Increased 2025 capex guidance no surprise but no early hints for 2026 3. Custom silicon, price, and incumbent workloads define the long-term AWS AI strategy 4. Tariff uncertainty weighs on retail outlook, but underlying fundamentals remain strong
JD.com to Report Second Quarter and Interim 2025 Financial Results on August 14, 2025 BEIJING, July 31, 2025 (GLOBE NEWSWIRE) -- JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter)), a leading supply chain-based technology and service provider, today announced that it plans to release its unaudited financial results for the three months and six months ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. market opens. JD.com’s management will hold a conference call at 8:00 am, Eastern Time on August 14, 2025, (8:00 pm, Beijing/Hong Kong Time on A...
JD.com Announces Decision to Make a Voluntary Public Takeover Offer and Strategic Investment Partnership with CECONOMY BEIJING, July 30, 2025 (GLOBE NEWSWIRE) -- JD.com, Inc. (“JD.com” or the “Company”) (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter)), a leading supply chain-based technology and service provider, today announced that it decided to make a voluntary public takeover offer, through a wholly-owned indirect subsidiary JINGDONG Holding Germany GmbH (the “Bidder”), to all shareholders of CECONOMY AG (“CECONOMY”) (XETRA: CEC), the parent company of leading Europea...
WAIC 2025 was held in Shanghai on 26-28 July under the theme "Intelligent Horizons, Shared Future". The focus of WAIC this year shifted from LLM to the next frontier – AI applications and AI agents. As AI capabilities extend from the cloud to edge devices, a transformative evolution in human-AI interaction is underway, characterised by more tangible, embodied forms and empathetic voice interfaces. Maintain MARKET WEIGHT.
With US GLP-1 volume growth in diabetes stalling to just 5%, we examine the evidence that Mounjaro’s high efficacy has resulted in a surge of patients getting to HbA1c goal & discontinuing treatment. We analyse the literature & clinical data that shows that GLP-1 market growth could slow dramatically for years to come given Mounjaro is now half the US GLP-1 volume in diabetics. We expect Mounjaro’s NBRx share to be >70% by end 2026, likely resulting in further downgrades to Ozempic consensus. Ba...
We have rolled up all our bottom-up AI analyses into ROIC estimates for GOOGL, AMZN and META through 2030. Key Conclusions: There are three distinct ROI profiles. • AMZN is the only one with positive ROIC today. • GOOGL has the highest ROIC in 2030. • META lags throughout the decade.
Wedbush Securities’ affiliated investment adviser, Wedbush Fund Advisers, LLC (“WFA”), may serve as the investment adviser to certain investment funds that track an index comprised exclusively of companies included in this research report. In connection with these funds, Wedbush Securities will rec
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.